PROMOMED became the winner of the Platinum Ounce Award in two nominations at once.

PROMOMED biopharmaceutical Company has won two nominations of one of the main industry awards — "Platinum Ounce". Peter Bely, Chairman of the Board of Directors of PROMOMED, became the winner of the "Senior Management" sub-nomination. The Tirzetta® brand was recognized as the winner in the sub-nomination "Lonch of the Year. The retail segment." The jury and independent experts noted the Company's leadership, the quality of its product portfolio and its contribution to the development of the Russian pharmaceutical market.

"In 2025, this leader found himself not only in the spotlight of the professional community, but also on the list of people the entire business world was already talking about. Under his leadership, the company increased revenue by 75.2% last year, and revenue amounted to 38 billion rubles. So, the winner in the Senior Management sub—nomination is Peter Bely, Chairman of the Board of Directors of PROMOMED," the award ceremony announced. This assessment of managerial leadership is directly related to the results of product teams and the market success of the Company's portfolio.

This course was confirmed by one of the most notable launches of 2025, Tirzetta®: the brand quickly reached federal coverage and was highly appreciated by the professional community. This is the first Russian drug based on a unique active ingredient — tirzepatide. The drug is available in the form of a solution in disposable injectors and is used only once a week. This form of drug delivery made it possible to develop a formula without preservatives, making therapy more accessible to a larger number of patients with concomitant diseases.

The Platinum Ounce is one of the oldest and most respected professional awards in the Russian pharmaceutical market. The award has been held since 2000. Its purpose is to celebrate companies, brands, projects and leaders who make the greatest contribution to the development of the industry.

The award's victories were a recognition of the Company's leadership positions, the effectiveness of its product strategy and management decisions, as well as its contribution to the development of the domestic pharmaceutical market and increasing the availability of modern therapy for patients.